Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001209191-20-049430

Chief Financial Officer sold 12,000 shares at an average $92.26 ($1,107,068)

  • Chief Financial Officer acquired 12,000 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
TOMSICEK MICHAEL JOHN Chief Financial Officer 2020-09-01 Option exercise +12,000 $17.75 $213,000 12,410 D
TOMSICEK MICHAEL JOHN Chief Financial Officer 2020-09-01 Sale −2,800 $91.39 $255,892 9,610 D
TOMSICEK MICHAEL JOHN Chief Financial Officer 2020-09-01 Sale −6,400 $92.23 $590,272 3,210 D
TOMSICEK MICHAEL JOHN Chief Financial Officer 2020-09-01 Sale −2,800 $93.18 $260,904 410 D
Derivatives
TOMSICEK MICHAEL JOHN Chief Financial Officer 2020-09-01 Option exercise · Stock Option (Right to Buy) −12,000 156,000 D
Open-market sales · 12,000 sh · avg $92.26 · $1,107,068
Loading xslF345X03/doc4.xml…